Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma

The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC....

Full description

Bibliographic Details
Main Authors: Lingling Zhu, Yanyang Liu, Honglin Gao, Jiewei Liu, Qinghua Zhou, Feng Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
non-small cell lung cancer
immune checkpoint blockade
EGFR exon 20 mutation
histological transformation
immune therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.755135/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.755135/full

Similar Items